This tool focuses on the role of stigma at the intersection of HIV and OUD systems, and introduces opportunities for intervention at the systems level.
Breadcrumb
- Home
- Resources and Tools
Resources and Tools
A recent study published in Drug and Alcohol Dependence found evidence for racial/ethnic disparities in buprenorphine distribution across the United States.
Transgender people and communities, including nonbinary people, have specific needs within harm reduction programs.
In recent years, the gap in the rate of opioid overdoses among Black and white Americans has narrowed significantly, with increases in Black mortality driven in part by the addition of synthetic opioids to other drugs.
This technical package, a collaborative effort between CDC and NASTAD, provides a broad framework as well as evidence-informed strategies and approaches to support the planning, design, implementation, and sustainability of new and existing syringe services programs (SSPs).
Opioid agonist treatment (OAT) is the provision of medications (methadone and buprenorphine) that activate the opioid receptors to prevent withdrawal and reduce cravings for opioids.
This publication, part of SAMHSA's Evidence Based Resource Guide series, addresses the co-occurrence of HIV and mental illness and/or SUD.
This article describes how the HIV testing window period is a challenge related to prescribing PrEP for people who inject drugs, and discusses current approaches and how data are needed to help guide best practices.
This virtual session summary describes key takeaways from the August 2020 Let's Talk about SSPs as Essential Services conversation.
Pagination
- Previous page ‹‹
- Page 2
- Next page ››